WO2007110705A3 - Compositions macrolides en tant qu'agents thérapeutiques - Google Patents

Compositions macrolides en tant qu'agents thérapeutiques Download PDF

Info

Publication number
WO2007110705A3
WO2007110705A3 PCT/IB2006/004214 IB2006004214W WO2007110705A3 WO 2007110705 A3 WO2007110705 A3 WO 2007110705A3 IB 2006004214 W IB2006004214 W IB 2006004214W WO 2007110705 A3 WO2007110705 A3 WO 2007110705A3
Authority
WO
WIPO (PCT)
Prior art keywords
mhc class
macrolide
inhibitors
cancer
related disorders
Prior art date
Application number
PCT/IB2006/004214
Other languages
English (en)
Other versions
WO2007110705A2 (fr
Inventor
Bernard Mach
Peter Traxler
Krzysztof Masternak
Antony David Buss
Stephen Robert Whitton
Mark Stuart Butler
Yogonathan Kanagasundaram
Horst Flotow
Guo Xuming
Mui Mui Sim
Chee Wee Phoon
Original Assignee
Novimmune Sa
Merlion Pharmaceuticals Pte Lt
Bernard Mach
Peter Traxler
Krzysztof Masternak
Antony David Buss
Stephen Robert Whitton
Mark Stuart Butler
Yogonathan Kanagasundaram
Horst Flotow
Guo Xuming
Mui Mui Sim
Chee Wee Phoon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novimmune Sa, Merlion Pharmaceuticals Pte Lt, Bernard Mach, Peter Traxler, Krzysztof Masternak, Antony David Buss, Stephen Robert Whitton, Mark Stuart Butler, Yogonathan Kanagasundaram, Horst Flotow, Guo Xuming, Mui Mui Sim, Chee Wee Phoon filed Critical Novimmune Sa
Publication of WO2007110705A2 publication Critical patent/WO2007110705A2/fr
Publication of WO2007110705A3 publication Critical patent/WO2007110705A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés macrolides, ainsi que des sels pharmaceutiquement acceptables de ceux-ci, qui inhibent l'expression de la MHC de classe II et qui peuvent être utilisés en tant qu'agents immunosuppresseurs dans le traitement avant, pendant et/ou après une greffe d'organe ou de tissus, ainsi que dans le traitement de troubles immunitaires et/ou du cancer et de troubles liés au cancer.
PCT/IB2006/004214 2005-09-28 2006-09-27 Compositions macrolides en tant qu'agents thérapeutiques WO2007110705A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72155605P 2005-09-28 2005-09-28
US60/721,556 2005-09-28

Publications (2)

Publication Number Publication Date
WO2007110705A2 WO2007110705A2 (fr) 2007-10-04
WO2007110705A3 true WO2007110705A3 (fr) 2007-11-29

Family

ID=38508745

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/004214 WO2007110705A2 (fr) 2005-09-28 2006-09-27 Compositions macrolides en tant qu'agents thérapeutiques

Country Status (1)

Country Link
WO (1) WO2007110705A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080312317A1 (en) * 2007-04-12 2008-12-18 Eisai R&D Management Co., Ltd. 12 membered-ring macrolactam derivatives
GB0821539D0 (en) * 2008-11-25 2008-12-31 Merlion Pharmaceuticals Pte Ltd Therapeutic compounds and their use
WO2013148324A1 (fr) * 2012-03-26 2013-10-03 The Regents Of The University Of California Composés de polycétides anticancéreux
MX2020010606A (es) 2018-04-09 2021-01-15 Eisai R&D Man Co Ltd Compuestos de pladienolida y su uso.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997016425A1 (fr) * 1995-10-30 1997-05-09 Merck & Co., Inc. Nouveaux inhibiteurs de la liaison de peptides avec des proteines de classe ii du complexe d'histocompatibilite majeur
EP1548121A1 (fr) * 2002-07-31 2005-06-29 Mercian Corporation Nouvelles substances actives sur le plan physiologique

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997016425A1 (fr) * 1995-10-30 1997-05-09 Merck & Co., Inc. Nouveaux inhibiteurs de la liaison de peptides avec des proteines de classe ii du complexe d'histocompatibilite majeur
EP1548121A1 (fr) * 2002-07-31 2005-06-29 Mercian Corporation Nouvelles substances actives sur le plan physiologique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SEKI-ASANO M ET AL: "ISOLATION AND CHARACTERIZATION OF A NEW 12-MEMBERED MACROLIDE FD-895", JOURNAL OF ANTIBIOTICS, JAPAN ANTIBIOTICS RESEARCH ASSOCIATION, TOKYO, JP, vol. 47, no. 12, December 1994 (1994-12-01), pages 1395 - 1401, XP002951021, ISSN: 0021-8820 *

Also Published As

Publication number Publication date
WO2007110705A2 (fr) 2007-10-04

Similar Documents

Publication Publication Date Title
WO2007087068A3 (fr) Inhibiteurs de tyrosine kinase et leurs utilisations
WO2005105780A3 (fr) Compositions utiles en tant qu'inhibiteurs de la rock et d'autres proteines kinases
IL184898A0 (en) Pyrrolopyrimidine derivatives and pharmaceutical compositions containing the same
WO2005103050A3 (fr) Azaindoles utiles en tant qu'inhibiteurs de la proteine serine/threonine kinase superhelice de la famille rho (rock) et d'autres proteines kinases
MX2009008253A (es) Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
ZA201201391B (en) Methods, compositions, and kits for the treatment of medical conditions
TW200633980A (en) Pyridones useful as inhibitors of kinases
MX2009006345A (es) Compuestos utiles como inhibidores de proteina cinasa.
WO2007064872A3 (fr) Composes de l'uree utilises dans le traitement du cancer
WO2007011962A3 (fr) Traitement du cancer
WO2005028475A3 (fr) Compositions utiles pour inhiber des proteines kinases
WO2007095188A3 (fr) Dihydrodiazepines servant d'inhibiteurs des proteines kinases
EP2476679A3 (fr) Triazoles substitués utilisés comme inhibiteurs AXL
MX2008011633A (es) Aminoquinolonas como inhibidores de gsk-3.
EP2476461A3 (fr) Formulations pour le traitement du cancer
WO2008039218A3 (fr) Inhibiteurs de la tyrosine kinase de bruton
WO2008003007A3 (fr) Compositions et procédés destinés au traitement d'infections parasitaires
MX2009012719A (es) Tiazoles y pirazoles utiles como inhibidores de cinasa.
WO2007016338A3 (fr) Utilisation d’inhibiteurs de la chk2 kinase pour le traitement du cancer
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
WO2007139816A3 (fr) Thiophène-carboxamides pouvant être employés en tant qu'inhibiteurs de protéine kinase
TW200745088A (en) Benzimidazoles useful as inhibitors of protein kinases
WO2007146335A3 (fr) Composés et compositions pour le traitement du cancer
WO2009035634A3 (fr) Cyanoaminoquinolones et tétrazoloaminoquinolones en tant qu'inhibiteurs de gsk-3
MX2009005231A (es) Composiciones utiles como inhibidores de proteina cinasa.

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06849545

Country of ref document: EP

Kind code of ref document: A2

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC ( EPO COMMUNICATIONS (FORMS 1205A: 05.06.2008 10.07.2008 )

122 Ep: pct application non-entry in european phase

Ref document number: 06849545

Country of ref document: EP

Kind code of ref document: A2